Trials / Active Not Recruiting
Active Not RecruitingNCT06073587
The CARDIO-TTRansform Scintigraphy Sub-study
CARDIO-TTRansform ION-682884-CS2-Scintigraphy Sub-study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.
Detailed description
Participants who were randomized in Study ION-682884-CS2 (NCT04136171) and have had a baseline scintigraphy scan will be offered the opportunity to participate in this sub-study which involves optional scintigraphy scans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Scintigraphy scan | Scans will be performed as specified in the arm description. |
Timeline
- Start date
- 2023-04-04
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2023-10-10
- Last updated
- 2025-11-28
Locations
5 sites across 2 countries: United States, Spain
Source: ClinicalTrials.gov record NCT06073587. Inclusion in this directory is not an endorsement.